CXCR4 and breast carcinoma: The encouraging data supporting the ability of ligand-activated PPARγ in blocking the SDF-1α/CXCR4 axis in breast cancer in vitro models represent a good starting point for further clinical studies investigating the possible action of PPARγ ligands in reducing breast cancer metastasis though the regulation of this pathway [7].